The longstanding frustration with CAR-T cell therapy in solid tumors — poor penetration, antigen escape, hostile microenvironments — has pushed researchers toward macrophages as an alternative cellular weapon. Macrophages naturally infiltrate solid tumors, and engineering them to carry chimeric antigen receptors (CARs) could overcome barriers that defeat T-cell approaches. A new strategy published in ACS Nano takes this concept further by eliminating the need for any ex vivo cell manipulation entirely.
The approach centers on ionizable cationic lipid-assisted polymeric nanoparticles (iCLANs), engineered to preferentially target macrophages in vivo. These particles co-deliver two mRNA payloads simultaneously: one encoding a CAR molecule targeting a specific tumor antigen, and one encoding interferon-gamma (IFN-γ), a cytokine that drives macrophages toward an M1 pro-inflammatory, anti-tumor phenotype. When injected intravenously into mouse models of EGFRvIII-positive breast cancer and CD19-positive B-cell lymphoma, the nanoparticles successfully transfected tumor-associated macrophages in situ, converting them into functional CAR-Ms expressing both the receptor and IFN-γ simultaneously. Significant tumor growth inhibition was observed alongside measurable remodeling of the immunosuppressive tumor microenvironment in both models.
This work addresses a core bottleneck in CAR-M therapy: ex vivo manufacturing of patient-derived macrophages is labor-intensive, costly, and yield-limited. By generating CAR-Ms directly within the tumor, this platform sidesteps those constraints. The dual mRNA payload is particularly clever — without concurrent IFN-γ expression, in vivo-generated CAR-Ms risk being repolarized to an M2 pro-tumor state by the immunosuppressive milieu, undermining the entire strategy. Contextually, this builds on the broader mRNA delivery revolution catalyzed by COVID-19 vaccines, now being adapted for oncology. Key limitations remain: all data are preclinical animal models, antigen specificity requires pre-selection, and long-term durability of the M1 phenotype is unproven. Whether iCLAN-based delivery achieves adequate tumor penetration and macrophage selectivity in human tumors at scale remains an open and critical question. Nonetheless, this is a conceptually significant advance worth tracking closely.